Dysplasia-detection rates highest in first year after Barrett's ablation

Reuters Health Information: Dysplasia-detection rates highest in first year after Barrett's ablation

Dysplasia-detection rates highest in first year after Barrett's ablation

Last Updated: 2018-06-28

By Will Boggs MD

NEW YORK (Reuters Health) - Dysplasia-detection rates are highest in the first year after successful endoscopic eradication of Barrett's esophagus, according to a new meta-analysis.

"We have traditionally believed that the progression from normal squamous esophageal mucosal to dysplastic Barrett's esophagus is a multistep process which takes a long time," Dr. Tarek Sawas from Mayo Clinic, in Rochester, Minnesota, told Reuters Health by email. "The high detection rate of dysplasia in the first year argues against these lesions being true recurrences and in favor of incompletely treated missed prevalent disease."

Several studies have reported high rates of esophageal adenocarcinoma (EAC) and high-grade dysplasia (HGD) in the first year after index endoscopy.

Dr. Sawas's team estimated the detection of intestinal metaplasia (IM), dysplasia and cancer in the first and subsequent years following complete remission of intestinal metaplasia (CRIM) in their systematic review and meta-analysis of 22 studies, including 1,973 patients with 5,176 patient-years of follow-up.

The incidence of IM detection per patient-year after achieving CRIM was 12% in year 1, 7% in year 2, and 3% in year 3, the researchers report in The American Journal of Gastroenterology, online June 14.

The dysplasia-detection rate was significantly higher in the first year after CRIM (3% per patient-year) than in subsequent years (1% per patient-year) and the HGD/EAC detection rate was nonsignificantly higher in the first year (1% per patient-year) than in subsequent years (0%).

The differences persisted regardless of endoscopic treatment, CRIM definition, acquisition of gastroesophageal junction biopsies during surveillance and baseline histology.

"These findings emphasize the importance of close surveillance in the first year after CRIM," Dr. Sawas said. "Surveillance intervals after year 1 should be continued but perhaps may be able to be expanded if others continue to demonstrate the relatively low rate of progression now that we know a large proportion of these patients really had prevalent dysplasia and cancer."

"There is a need for aggressive early surveillance after CRIM which requires careful and studied endoscopic visualization using at least high-definition endoscopy and probably narrow-band imaging," he added.

"This study by no means deemphasizes the continued need for long-term surveillance after successful endoscopic therapy nor the need to fully eradicate all intestinal metaplasia," Dr. Sawas concluded. "It does, however, challenge some of our current thoughts on surveillance after Barrett's ablation."

SOURCE: https://go.nature.com/2N6uU7u

Am J Gastroenterol 2018.

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.